These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 15019165

  • 1. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
    Hornung R, Urs E, Serenella E, Edward W, Ursula S, Urs H, Daniel F.
    Cancer Lett; 2004 Mar 31; 206(1):97-106. PubMed ID: 15019165
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.
    Oncol Rep; 2007 Nov 31; 18(5):1051-9. PubMed ID: 17914554
    [Abstract] [Full Text] [Related]

  • 3. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A, Jovanovic D, Jelic S.
    J BUON; 2009 Nov 31; 14(4):635-9. PubMed ID: 20148455
    [Abstract] [Full Text] [Related]

  • 4. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome.
    Bagnoli M, Ambrogi F, Pilotti S, Alberti P, Ditto A, Barbareschi M, Galligioni E, Biganzoli E, Canevari S, Mezzanzanica D.
    Endocr Relat Cancer; 2009 Jun 31; 16(2):443-53. PubMed ID: 19321593
    [Abstract] [Full Text] [Related]

  • 5. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z, Li YF, Liu FY, Feng YL, Hou JH, Zhao MQ.
    Ai Zheng; 2007 Mar 31; 26(3):312-7. PubMed ID: 17355798
    [Abstract] [Full Text] [Related]

  • 6. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer.
    Borgoño CA, Kishi T, Scorilas A, Harbeck N, Dorn J, Schmalfeldt B, Schmitt M, Diamandis EP.
    Clin Cancer Res; 2006 Mar 01; 12(5):1487-93. PubMed ID: 16533772
    [Abstract] [Full Text] [Related]

  • 7. Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIc serous cystadenocarcinoma of the ovary.
    Geisler JP, Wiemann MC, Miller GA, Geisler HE.
    Gynecol Oncol; 1996 Mar 01; 60(3):424-7. PubMed ID: 8774651
    [Abstract] [Full Text] [Related]

  • 8. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, Watanabe A, Ochiai K, Yasuda M, Tanaka T.
    Gynecol Oncol; 2004 Sep 01; 94(3):735-9. PubMed ID: 15350366
    [Abstract] [Full Text] [Related]

  • 9. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK, Chao TK, Yu CP, Yu MH, Jin JS.
    APMIS; 2009 Mar 01; 117(3):162-75. PubMed ID: 19245589
    [Abstract] [Full Text] [Related]

  • 10. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
    Lösch A, Schindl M, Kohlberger P, Lahodny J, Breitenecker G, Horvat R, Birner P.
    Gynecol Oncol; 2004 Feb 01; 92(2):545-52. PubMed ID: 14766246
    [Abstract] [Full Text] [Related]

  • 11. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD, Petrescu A, Waller M, Dina I.
    Rom J Morphol Embryol; 2008 Feb 01; 49(3):327-38. PubMed ID: 18758637
    [Abstract] [Full Text] [Related]

  • 12. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
    Kowalski LD, Kanbour AI, Price FV, Finkelstein SD, Christopherson WA, Seski JC, Naus GJ, Burnham JA, Kanbour-Shakir A, Edwards RP.
    Cancer; 1997 Apr 15; 79(8):1587-94. PubMed ID: 9118043
    [Abstract] [Full Text] [Related]

  • 13. [Assessment of prognostic factors in common ovarian tumors of varying malignancy].
    Demeter A, Várkonyi T, Csapó Z, Szánthó A, Oláh J, Papp Z.
    Magy Onkol; 2004 Apr 15; 48(3):259-65. PubMed ID: 15520877
    [Abstract] [Full Text] [Related]

  • 14. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients.
    Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, Zeillinger R.
    Anticancer Res; 1997 Apr 15; 17(1B):613-9. PubMed ID: 9066588
    [Abstract] [Full Text] [Related]

  • 15. B7-H4 overexpression in ovarian tumors.
    Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR.
    Gynecol Oncol; 2006 Jan 15; 100(1):44-52. PubMed ID: 16256178
    [Abstract] [Full Text] [Related]

  • 16. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Jan 15; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ.
    Lancet Oncol; 2013 Aug 15; 14(9):853-62. PubMed ID: 23845225
    [Abstract] [Full Text] [Related]

  • 19. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
    Steiner E, Pollow K, Hasenclever D, Schormann W, Hermes M, Schmidt M, Puhl A, Brulport M, Bauer A, Petry IB, Koelbl H, Hengstler JG.
    Gynecol Oncol; 2008 Mar 15; 108(3):569-76. PubMed ID: 18222533
    [Abstract] [Full Text] [Related]

  • 20. Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor.
    Fujiwara S, Nawa A, Nakanishi T, Shimoyama Y, Kajiyama H, Shibata K, Ino K, Nakamura S, Kikkawa F, Yatabe Y.
    Hum Pathol; 2010 Apr 15; 41(4):560-5. PubMed ID: 20004952
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.